

Andreas Pircher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6102905/publications.pdf>

Version: 2024-02-01

106
papers

4,410
citations

186265

28
h-index

118850

62
g-index

109
all docs

109
docs citations

109
times ranked

8157
citing authors

#	ARTICLE	IF	CITATIONS
1	Phenotype molding of stromal cells in the lung tumor microenvironment. <i>Nature Medicine</i> , 2018, 24, 1277-1289.	30.7	1,126
2	Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy. <i>Cancer Cell</i> , 2016, 30, 968-985.	16.8	464
3	An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates. <i>Cancer Cell</i> , 2020, 37, 21-36.e13.	16.8	253
4	Single-Cell RNA Sequencing Maps Endothelial Metabolic Plasticity in Pathological Angiogenesis. <i>Cell Metabolism</i> , 2020, 31, 862-877.e14.	16.2	169
5	Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook. <i>Molecular Cancer</i> , 2020, 19, 141.	19.2	141
6	Serine Synthesis via PHGDH Is Essential for Heme Production in Endothelial Cells. <i>Cell Metabolism</i> , 2018, 28, 573-587.e13.	16.2	127
7	Longitudinal analysis of 2293 NSCLC patients: A comprehensive study from the TYROL registry. <i>Lung Cancer</i> , 2015, 87, 193-200.	2.0	115
8	Treg(s) in Cancer: Friends or Foe?. <i>Journal of Cellular Physiology</i> , 2015, 230, 2598-2605.	4.1	105
9	BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. <i>Blood</i> , 2016, 127, 2847-2855.	1.4	100
10	Tumor Endothelial Cells (TECs) as Potential Immune Directors of the Tumor Microenvironment – New Findings and Future Perspectives. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 766.	3.7	99
11	Targeting the Tumor Microenvironment in Renal Cell Cancer Biology and Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 490.	2.8	85
12	Meta-analysis of clinical metabolic profiling studies in cancer: challenges and opportunities. <i>EMBO Molecular Medicine</i> , 2016, 8, 1134-1142.	6.9	83
13	Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 293-305.	3.7	80
14	Targeting the insulin-like growth factor network in cancer therapy. <i>Cancer Biology and Therapy</i> , 2011, 11, 701-707.	3.4	76
15	Tumor vessel disintegration by maximum tolerable PFKFB3 blockade. <i>Angiogenesis</i> , 2017, 20, 599-613.	7.2	73
16	EndoDB: a database of endothelial cell transcriptomics data. <i>Nucleic Acids Research</i> , 2019, 47, D736-D744.	14.5	70
17	Biomarkers in Tumor Angiogenesis and Anti-Angiogenic Therapy. <i>International Journal of Molecular Sciences</i> , 2011, 12, 7077-7099.	4.1	66
18	Endothelial cell metabolism: A novel player in atherosclerosis? Basic principles and therapeutic opportunities. <i>Atherosclerosis</i> , 2016, 253, 247-257.	0.8	62

#	ARTICLE	IF	CITATIONS
19	PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy. <i>Oncotarget</i> , 2017, 8, 66849-66864.	1.8	47
20	Endothelial Progenitor Cells: Current Issues on Characterization and Challenging Clinical Applications. <i>Stem Cell Reviews and Reports</i> , 2012, 8, 926-939.	5.6	46
21	Neoadjuvant chemo-immunotherapy modifies CD4+CD25+ regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients. <i>Lung Cancer</i> , 2014, 85, 81-87.	2.0	44
22	Vessel pruning or healing: endothelial metabolism as a novel target?. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 239-247.	3.4	42
23	Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2291.	4.1	40
24	The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets. <i>PLoS ONE</i> , 2018, 13, e0202045.	2.5	40
25	Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 138, 248-256.	2.5	36
26	Anti-Angiogenics: Their Value in Colorectal Cancer Therapy. <i>Oncology Research and Treatment</i> , 2018, 41, 188-193.	1.2	35
27	Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance. <i>Cardiovascular Research</i> , 2020, 116, 970-982.	3.8	32
28	Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer. <i>Molecular Cancer</i> , 2022, 21, .	19.2	32
29	Liver cancer: Targeted future options. <i>World Journal of Hepatology</i> , 2011, 3, 38.	2.0	31
30	Small steps of improvement in small-cell lung cancer (SCLC) within two decades: A comprehensive analysis of 484 patients. <i>Lung Cancer</i> , 2014, 84, 168-174.	2.0	27
31	Low-dose vemurafenib in hairy cell leukemia patients with active infection. <i>American Journal of Hematology</i> , 2019, 94, E180-E182.	4.1	27
32	ASCO 2020 non-small lung cancer (NSCLC) personal highlights. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 66-69.	0.5	27
33	ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer—results from an international multicenter study. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 271-275.	3.9	25
34	High Risk of Under-Grading and -Staging in Prostate Cancer Patients Eligible for Active Surveillance. <i>PLoS ONE</i> , 2015, 10, e0115537.	2.5	24
35	Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non-small-cell Lung Cancer (NSCLC): A Report of 2 Cases. <i>Clinical Lung Cancer</i> , 2019, 20, e247-e250.	2.6	24
36	The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer – New Combinational Approaches and Strategies of Neovessel Inhibition. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 610903.	3.7	24

#	ARTICLE	IF	CITATIONS
37	High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2021, 10, 304-313.	2.8	23
38	Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC). <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 102948.	4.4	21
39	Favorable prognosis of operable non-small cell lung cancer (NSCLC) patients harboring an increased expression of tumor endothelial markers (TEMs). <i>Lung Cancer</i> , 2013, 81, 252-258.	2.0	20
40	Increased numbers of endothelial progenitor cells in peripheral blood and tumor specimens in non-small cell lung cancer: a methodological challenge and an ongoing debate on the clinical relevance. <i>Oncology Reports</i> , 2008, 19, 345-52.	2.6	19
41	New Antiangiogenic Strategies beyond Inhibition of Vascular Endothelial Growth Factor with Special Focus on Axon Guidance Molecules. <i>Oncology</i> , 2014, 86, 46-52.	1.9	18
42	Incidental Diagnosis of Asymptomatic Non-Small-Cell Lung Cancer: A Registry-Based Analysis. <i>Clinical Lung Cancer</i> , 2016, 17, 62-67.e1.	2.6	18
43	Angiogenesis inhibition in non-small cell lung cancer: a critical appraisal, basic concepts and updates from American Society for Clinical Oncology 2019. <i>Current Opinion in Oncology</i> , 2020, 32, 44-53.	2.4	18
44	A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?. <i>European Urology Oncology</i> , 2021, 4, 745-754.	5.4	17
45	BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials. <i>Leukemia</i> , 2020, 34, 1454-1457.	7.2	16
46	Basic clinical parameters predict gefitinib efficacy in non-small cell lung cancer. <i>Anticancer Research</i> , 2011, 31, 2949-55.	1.1	15
47	Cancer Stem Cells: Characteristics and Their Potential Role for New Therapeutic Strategies. <i>Onkologie</i> , 2011, 34, 269-274.	0.8	14
48	Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms. <i>Thrombosis and Haemostasis</i> , 2011, 105, 72-80.	3.4	14
49	Antidiabetic drugs influence molecular mechanisms in prostate cancer. <i>Cancer Biology and Therapy</i> , 2018, 19, 1153-1161.	3.4	14
50	Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies. <i>Oncotarget</i> , 2016, 7, 20109-20123.	1.8	14
51	Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial). <i>Lung Cancer</i> , 2014, 85, 395-400.	2.0	13
52	The Impact of Cand1 in Prostate Cancer. <i>Cancers</i> , 2020, 12, 428.	3.7	13
53	Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients. <i>Lung Cancer</i> , 2010, 69, 265-271.	2.0	12
54	ASCO 2018 NSCLC highlights – combination therapy is key. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 266-271.	0.5	12

#	ARTICLE	IF	CITATIONS
55	Prognostic Value of Testing PD-L1 Expression After Radical Cystectomy in High-risk Patients. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1015-e1024.	1.9	12
56	Deregulated glutamate to pro-collagen conversion is associated with adverse outcome in lung cancer and may be targeted by renin-angiotensin-aldosterone system (RAS) inhibition. <i>Lung Cancer</i> , 2021, 159, 84-95.	2.0	12
57	Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210819.	3.2	12
58	Docetaxel in the treatment of non-small cell lung cancer (NSCLC) – an observational study focusing on symptom improvement. <i>Anticancer Research</i> , 2013, 33, 3831-6.	1.1	10
59	Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 890-891.	27.0	9
60	Increased numbers of endothelial progenitor cells in peripheral blood and tumor specimens in non-small cell lung cancer: A methodological challenge and an ongoing debate on the clinical relevance. <i>Oncology Reports</i> , 2008, , .	2.6	8
61	Evidence-based follow-up in lung cancer?. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 73-77.	0.5	8
62	The Biology of Classic Hairy Cell Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7780.	4.1	8
63	Differential procoagulatory response of microvascular, arterial and venous endothelial cells upon inflammation in vitro. <i>Thrombosis Research</i> , 2021, 205, 70-80.	1.7	8
64	Hairy Cell Leukemia Patients Have a Normal Life Expectancy – A 35-Year Single-Center Experience and Comparison with the General Population. <i>Cancers</i> , 2022, 14, 1242.	3.7	8
65	Targeting angiogenesis in lung cancer - Pitfalls in drug development. <i>Translational Lung Cancer Research</i> , 2012, 1, 122-8.	2.8	7
66	Multicenter Phase II Study Evaluating Two Cycles of Docetaxel, Cisplatin and Cetuximab as Induction Regimen Prior to Surgery in Chemotherapy-Naive Patients with NSCLC Stage IB-III A (INN06-Study). <i>PLoS ONE</i> , 2015, 10, e0125364.	2.5	6
67	High CXCR4 expression in pancreatic ductal adenocarcinoma as characterized by an inflammatory tumor phenotype with potential implications for an immunotherapeutic approach.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4021-4021.	1.6	6
68	Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient. <i>Lung Cancer</i> , 2014, 83, 408-410.	2.0	5
69	Robo 4 - the double-edged sword in prostate cancer: impact on cancer cell aggressiveness and tumor vasculature. <i>International Journal of Medical Sciences</i> , 2019, 16, 115-124.	2.5	5
70	Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial. <i>Translational Andrology and Urology</i> , 2018, 7, S132-S134.	1.4	4
71	Atezolizumab for PD-L1 – Selected Patients with NSCLC. <i>New England Journal of Medicine</i> , 2021, 384, 583-585.	27.0	4
72	Revival of anti-angiogenic therapies in cancer – news on an old therapeutic concept. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 185-186.	0.5	3

#	ARTICLE	IF	CITATIONS
73	BRAF Inhibition in Hairy Cell Leukemia: Multicentre Experience of 21 Patients Treated with Vemurafenib. <i>Blood</i> , 2014, 124, 3634-3634.	1.4	3
74	Polyarteritis nodosa complicating multiple myeloma – a case report and review of the literature. , 2014, 33, 143-157.		3
75	Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study. <i>Anticancer Research</i> , 2015, 35, 5129-39.	1.1	3
76	Biomarkers of angiogenesis and their role in clinical oncology. <i>Memo - Magazine of European Medical Oncology</i> , 2010, 3, 27-32.	0.5	2
77	Creating the “new normal” post-Coronavirus world” web-communication replacing face-to-face interaction. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 245-246.	0.5	2
78	ASCO 2021” selection of personal highlights in early stage non-small cell lung cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 347.	0.5	2
79	Paraneoplastic phenomena and diagnostic challenges in angioimmunoblastic T-cell lymphoma (AITL): report of two cases and review of the literature. <i>In Vivo</i> , 2014, 28, 327-32.	1.3	2
80	Molecular oncology in lung cancer – between biomarkers and clinical application. Relevance of the Ras/Raf/MEK/ERK pathway. <i>Memo - Magazine of European Medical Oncology</i> , 2011, 4, 242-247.	0.5	1
81	Durable complete remission in a patient with recurrent DLBCL receiving rituximab monotherapy after high-dose chemotherapy and autologous stem cell transplantation. <i>BMJ Case Reports</i> , 2012, 2012, bcr0220125856-bcr0220125856.	0.5	1
82	Is there a role for angiogenesis inhibition in prostate cancer?. <i>Memo - Magazine of European Medical Oncology</i> , 2014, 7, 214-218.	0.5	1
83	Reply. <i>Clinical Lung Cancer</i> , 2016, 17, e187.	2.6	1
84	Re: Erik Bovinder Ylitalo, Elin Thysell, Emma Jernberg, et al. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response. <i>Eur Urol</i> 2017;71:776–87. <i>European Urology</i> , 2017, 72, e102-e103.	1.9	1
85	Cholesterol pathway the Achilles heel in prostate cancer metastasis. <i>Translational Andrology and Urology</i> , 2018, 7, S686-S687.	1.4	1
86	Cloak and dagger – secondary hemophagocytic lymphohistiocytosis caused by intravenous autoinfection. <i>American Journal of Hematology</i> , 2020, 95, 330-332.	4.1	1
87	ESMO 2019” personal non-small lung cancer highlights. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 150-153.	0.5	1
88	Death of unknown cause? Post-mortem diagnosis of fulminant course of an EBV-associated secondary hemophagocytic lymphohistiocytosis. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 287-291.	0.5	1
89	Rare lung cancers” Primary pulmonary leiomyosarcoma: A case report. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 392-396.	0.5	1
90	Sorafenib in thyroid cancer” a retrospective case series. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 246-249.	0.5	0

#	ARTICLE	IF	CITATIONS
91	ASCO 2013: new developments in lung cancer. Memo - Magazine of European Medical Oncology, 2013, 6, 236-239.	0.5	0
92	NSCLC without Antineoplastic Treatment: Incidence, Characteristics, and Outcome as Outlined in the TYROL Study. Oncology, 2015, 89, 255-261.	1.9	0
93	Ulcerative skin metastases of primary lung cancer. Japanese Journal of Clinical Oncology, 2015, 45, 135-135.	1.3	0
94	Revival of anti-angiogenic therapies in cancer. Memo - Magazine of European Medical Oncology, 2018, 11, 1-2.	0.5	0
95	Overcoming resistance and bypassing checkpointsâ€”possible new therapeutic frontiers in oncology. Memo - Magazine of European Medical Oncology, 2019, 12, 105-106.	0.5	0
96	Saving lives with lung cancer screening. Memo - Magazine of European Medical Oncology, 2019, 12, 107-108.	0.5	0
97	ESMO 2018â€”personal highlights. Memo - Magazine of European Medical Oncology, 2019, 12, 67-70.	0.5	0
98	Young hematologists and medical oncologists in focus. Memo - Magazine of European Medical Oncology, 2020, 13, 9-10.	0.5	0
99	An update from the 2019 ESMO meeting. Memo - Magazine of European Medical Oncology, 2020, 13, 139-140.	0.5	0
100	Vaccination influenz(a)ing cancerâ€™specific survival. International Journal of Cancer, 2021, 148, 1806-1807.	5.1	0
101	D6-04: Increased numbers of endothelial progenitor cells in peripheral blood and tumour specimens in non small cell lung cancer patients. A methodological challenge and ongoing debate on the clinical relevance. Journal of Thoracic Oncology, 2007, 2, S408.	1.1	0
102	Results of the REGATTA trial on surgical therapy of limited metastatic gastric cancer: open issues and future perspectives. Translational Cancer Research, 2016, 5, S178-S181.	1.0	0
103	Cytotoxics and Anti-Angiogenics: Metronomic Therapies. , 2017, , 1-22.		0
104	Cytotoxics and Anti-angiogenics: Metronomic Therapies. , 2019, , 327-347.		0
105	Rare lung cancersâ€”2021 update on challenges, advances, and opportunities. Memo - Magazine of European Medical Oncology, 2021, 14, 317-318.	0.5	0
106	Breast implant-associated anaplastic large-cell lymphomaâ€”update on challenges, advances and opportunities. Memo - Magazine of European Medical Oncology, 0, , .	0.5	0